Citations

Clear

4207 citation(s) found for "Chen, Bo".

Beyond Breathing: Lung as a Sensory Organ A Report from the NHLBI Workshop on Lung Sensing and its Implication in Diseases
Jendzjowsky, Nicholas, Kuo, Christin S. , Chen, Zhijian, Li, Peng, Prescott, Sara , Liu, Yin, Seeholzer, Laura, Tschumperlin, Daniel J. , Taylor‐Clark, Thomas E. , Rajagopal, Jay, Haber, Adam L, Noel, A, Kotas, Maya, Drake, M G, Pabelick, C M, Rosenblatt, Jody , Mouradian, Gary, Su, Yujuan, Gomez, Christian, Lin, Q. , Lu, Qing , Mongodin, Emmanuel F. , Vuga, Louis, Zhou, Guofei , Prakash, Y S, Sun, X, Pabelick, Christina, Jendzjowsky, Nicholas Gregory , Reznikov, Leah R. , Li, Peng, Prescott, Sara, Seeholzer, Laura F. , Rajagopal, Jayaraj , Haber, Adam L., Kotas, Maya E. , Pabelick, Christina M. , Mouradian, Gary Charles , Gómez, Christian R. , Vuga, Louis J., Prakash, Y. S.

Mayo Clinic

American Journal of Respiratory Cell and Molecular Biology | June 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ajrcmb/aanag111 | PMID 42265991 Get It

Abstract The lung, one the largest branching organs in our body and vital for survival at first breath, is commonly known as the gas-exchange organ. Recent novel findings on lung sensing cells, molecules, and lung-brain crosstalk in the emerging discipline of interoception have highlighted the consideration of the lung as a sensory organ. Acknowledging the central importance of lung sensing to human health and disease, NHLBI convened a workshop to synthesize the past, current, and future of lung sensing research, with in-person presentations by ∼20 interdisciplinary experts and a large virtual audience. Here, we highlight the key topics discussed and summarize a blueprint for the future in this important field.
Germline regulation of tumor evolutionary dynamics shapes multiple myeloma progression
Chen, Hai, Shu, Jingmin, Wang, Panwen , Bergsagel, Leif, Yang, Ping, Shi, Changxin, Liu, Li, Mudappathi, Rekha , Liu, Li , Chen, Hai, Bergsagel, P. Leif , Sun, Zhifu

Mayo Clinic

No container title available | June 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.05.730550 | PMID 42282549 Get It

ABSTRACT Germline variation shapes cancer risk, yet its influence on the evolutionary dynamics of established tumors remains poorly understood. In multiple myeloma, subclonal diversification drives disease progression and treatment failure, but the heritable factors that modulate this process are unknown. Here, we show that germline variation is associated with tumor evolutionary features, implicating inherited regulation in subclonal expansion. Integrating germline variation with tumor evolutionary parameters identifies variants associated with evolutionary features, with signals enriched in regulatory regions, consistent with a transcriptional basis. We further identify TBKBP1 as a key locus linking germline variation to tumor evolution and clinical outcome. Germline variation at this locus is associated with TBKBP1 expression and subclonal expansion, and TBKBP1 expression correlates with adverse prognosis, consistent across independent cohorts. Functional analyses demonstrate that TBKBP1 promotes proliferation and activates MYC, mTORC1 and non-canonical NF-κB signaling pathway. Together, these findings establish germline regulatory variation as a determinant of tumor evolutionary dynamics and identify TBKBP1 as a mediator linking inherited variation to subclonal expansion and disease progression in multiple myeloma.
The effect of rocking speed and cell inoculation density on hepatic spheroid size: A simple method for size modulation
Megaly, Michael , Tobolt, Diane, Chen, A. W. , Namsrai, Bat‐Erdene, Fisher, Benjamin , Ramesh, Srivasupradha, Chimedtseren, Anudari, Nyberg, Scott L. , Clemens, Dr Mark, Lee, Charles Y., Finger, Erik B. , Tobolt, Diane, Rao, Joseph Sushil , Ramesh, Srivasupradha, Bischof, John C , Finger, Erik B. , Megaly, Michael G

Mayo Clinic

Bioengineering & Translational Medicine | June 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/btm2.70154 | PMID 42835954 Get It

Abstract Hepatic spheroids are widely used in bioartificial liver (BAL) systems, hepatotoxicology, and pharmacology due to improved functional stability compared with monolayer cultures. However, many existing methods rely on specialized equipment or static platforms that limit scalability and dynamic culture applications. Primary rat hepatocytes were cultured as three‐dimensional spheroids using a rocker‐based suspension system. Spheroid formation was evaluated across a range of rocking speeds (7–18 cycles per minute [cpm]) and inoculation densities. Spheroid morphology was quantified over time using two‐dimensional imaging. Functional performance was assessed by urea and albumin production on days 1, 4, 7, and 10. Spheroid formation efficiency was evaluated using volumetric modeling. Mean spheroid diameter decreased from 199 ± 41 μm at 7 cpm to 80.2 ± 17.6 μm at 18 cpm. The spheroid area was significantly influenced by both culture day ( p < 0.0001) and rocker speed, with significant differences observed across speeds at all time points ( p < 0.001, days 1–7). Mean spheroid area at 10 cpm was 13,750 ± 9051 μm 2 (day 1), 26,730 ± 8658 μm 2 (day 4), and decreased to 22,526 ± 8705 μm 2 (day 7). Urea production differed across speeds (ANOVA, p = 0.043), with peak performance at 12 cpm (median 3.47 μg/μg DNA) compared to 7 cpm (median 0.11 μg/μg DNA). Albumin production was 1086.8 ng/μg DNA on day 1 and 1534.4 ng/μg DNA on day 10. Urea production was 0.62 μg/μg DNA on day 1 and 1.25 μg/μg DNA on day 10. Median hepatocyte incorporation was 86% (range 73%–116%) by day 4. This rocker‐based method provides a simple, low‐cost, and scalable approach for generating hepatic spheroids with tunable size distributions under dynamic conditions. The system supports progressive functional maturation and is compatible with established scale‐up strategies, supporting its potential for translational applications.
Direct pharmacological targeting of asparagine synthetase to overcome resistance to L-asparaginase in ALL therapy
Claude, Rodney, Srivastava, Sankalp , Staschke, Kirk A., Fritz, Carlos A. Mellado, Chen, Shaoxiong, Liu, Lei, Zhong, Minghua, Lanman, Nadia A, Davé, Utpal P. , Batra, Sandeep , Zhou, Jiehao , Fang, Yue, Zhang, C , Kapur, Reuben , Wek, Ronald C., Zhang, Ji , Staschke, Kirk A. , Fritz, Carlos Mellado , Zhong, Minghua, Kothandaraman, Harish , Lanman, Nadia A. , Fan, Jing , Wek, Ronald C. , Zhang, Ji

Mayo Clinic

JCI Insight | June 4, 2026 | Volume: 11 | Issue: 14 | Pages: No page available

10.1172/jci.insight.203777 | PMID 42241118 Get It

Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, arising from both B and T cell lineages (B-ALL and T-ALL). Current therapy exploits ALL cells’ low expression of asparagine synthetase (ASNS) by using L-asparaginase, a bacterial enzyme that depletes circulating asparagine. However, resistance can emerge through induction of ASNS, mediated in part by the amino acid stress sensor GCN2. In this study, we addressed the efficacy of L-asparaginase in combination with genetic or pharmacological inhibition of GCN2 and the ASNS inhibitor ASX-173. Using a Kras G12D -driven mouse model of T-ALL, we found that GCN2 is dispensable for leukemogenesis. However, genetic inactivation or pharmacologic inhibition of GCN2 sensitized ALL cells to asparagine depletion, correlating with impaired ASNS induction. While GCN2 targeting enhanced sensitivity to asparagine depletion, a subset of Gcn2 –/– T-ALL cells retained high ASNS expression and remained resistant to L-asparaginase. Likewise, some human T-ALL cells with elevated ASNS levels were refractory to GCN2 inhibition even under asparagine-depleted conditions. When combined with L-asparaginase, ASX-173 effectively eliminated ASNS hi leukemic cells in vitro and in vivo. These findings suggest that direct targeting of ASNS provides therapeutic benefit in leukemias that express high levels of ASNS and are resistant to GCN2 inhibition under asparagine-depleted conditions.
Development and Validation of a Novel Conditional Event‐Free Survival Tool in Diffuse Large B‐Cell Lymphoma
Chen, Zhengming, Luan, Danny , Jørgensen, Rasmus Rask Kragh , El-Galaly, Tarec C., Nastoupil, Loretta J., Cerhan, James R. , Flowers, Christopher R., Link, Brian K., Lossos, Izidore S. , Stephens, Deborah M., Cohen, Jonathon, Nowakowski, Grzegorz, Bartlett, Nancy, Friedberg, Jonathan W. , Kahl, Brad S., Leonard, John P., Brown, Peter, Smedby, Karin E., Martin, Peter, El‐Galaly, Tarec Christoffer , Rask Kragh Jørgensen, Rasmus , Maurer, Matthew , El-Galaly, Tarec C , Cerhan, James R , Lossos, Izidore S , Habermann, Thomas , Jakobsen, Lasse Hjort , Maurer, Matthew J. , Nastoupil, Loretta J. , Flowers, Christopher R. , Link, Brian K. , Stephens, Deborah M. , Habermann, Thomas M. , Nowakowski, Grzegorz, Bartlett, Nancy L. , Kahl, Brad S. , Smedby, Karin E. , Jerkeman, Mats

Mayo Clinic

American Journal of Hematology | June 4, 2026 | Volume: 101 | Issue: 9 | Pages: 2137-2146

10.1002/ajh.70398 | PMID 42240061 Get It

ABSTRACT One quarter of patients with diffuse large B‐cell lymphoma (DLBCL) who achieve a complete response following front‐line therapy will eventually experience disease relapse. Existing prognostic models use baseline factors to predict outcomes from the start of initial therapy and are not intended for use following completion of treatment. We developed a conditional event‐free survival (cEFS) tool that predicts a patient's risk of lymphoma recurrence after completing front‐line therapy taking into consideration baseline risk characteristics plus the time the patient has been in remission. Model development used pooled and harmonized data from two observational cohorts and four randomized trials of patients with newly diagnosed DLBCL treated with immunochemotherapy and either achieving a complete response or not experiencing an event within 12 weeks of end of therapy. Cox proportional‐hazards regression modeling with backwards stepwise selection was utilized for model development. External validation was performed using a large independent data registry. In total, data from 2757 patients were used for model development. The risk of experiencing an event at a time point after having survived a period of time could be computed parsimoniously using four basic predictors: age, ECOG performance status grade, Ann Arbor stage, and lactate dehydrogenase level. C‐index in the model development cohort was 0.65 (95% CI, 0.63–0.68), compared to 0.64 (95% CI, 0.62–0.66) in the external validation cohort. We believe that this dynamic risk prediction tool will not only aid clinicians in providing data‐driven recommendations for surveillance, but also assist patients themselves with key decisions, such as family planning.
Contrast-Free Ultrasound Microvascular Imaging via Radiality and Similarity Weighting
Yin, Jingyi , Zhang, Jingke , Huang, Lijie , DeRuiter, Ryan M. , Ji, Kaipeng , Zhao, Yanzhe , Knoll, Kate M , Petersen, Kendra E , Wu, Tao , Zhu, Xiang, Krier, James D., Robinson, Kathryn A. , Lerman, Lilach O. , Petersen, Kendra E. , Yin, Jingyi , Zhang, Jingke , DeRuiter, Ryan , Lok, U‐Wai , Bentall, Andrew , Chen, Shigao , Huang, Chengwu

Mayo Clinic

IEEE Transactions on Ultrasonics | June 3, 2026 | Volume: 73 | Issue: 7 | Pages: 775-790

10.1109/tuson.2026.3699956 | PMID 42735122 Get It

Cryptic splicing in synaptic and membrane excitability genes links TDP-43 loss to neuronal dysfunction
Guo, Caiwei , Chen, Kuchuan , Vatsavayai, Sarat C. , Akiyama, Tetsuya , Liu, Chang , Zeng, Yi , Sianto, Odilia, Yang, Edith, Bombosch, Juliane, Powell, Rasheen , Zhen, Shannon , Mekhoubad, Shila, Miller, Georgiana, Ilic, Dragana , Boll, Moritz , Parnell, Euan, Penzes, Peter , Lipstein, Noa , Green, Eric M. , Petrucelli, Leonard , Seeley, William W. , Gitler, Aaron D. , Vatsavayai, Sarat , Zeng, Yi , Miller, Georgiana , Ilic, Dragana , Boll, Moritz , Penzes, Peter , Lipstein, Noa , Green, Eric M , Petrucelli, Leonard , Seeley, William , Gitler, Aaron D , Akiyama, Tetsuya , Yang, Edith, Morrie, Ryan D. , Parnell, Euan

Mayo Clinic

Science Translational Medicine | June 3, 2026 | Volume: 18 | Issue: 852 | Pages: No page available

10.1126/scitranslmed.aeb8517 | PMID 42234776 Get It

TAR DNA binding protein 43 (TDP-43) pathology is a defining pathological hallmark of multiple neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). A major feature of TDP-43 pathology is its nuclear depletion, leading to the aberrant inclusion of cryptic exons during RNA splicing. STMN2 and UNC13A have emerged as prominent TDP-43 splicing targets, but the broader impact of TDP-43–dependent cryptic splicing on neuronal function remains unclear. Here, we report previously unidentified TDP-43 splicing targets critical for membrane excitability and synaptic function, including KALRN , RAP1GAP , SYT7 , and KCNQ2 . Using human stem cell–derived neurons, we showed that TDP-43 reduction induces cryptic splicing and down-regulation of these genes, resulting in impaired excitability and synaptic transmission. In postmortem brains from patients with FTD, these cryptic splicing events occurred selectively in neurons with TDP-43 pathology. Suppressing individual cryptic splicing events using antisense oligonucleotides partially restored neuronal function, and combined targeting almost fully rescued the synaptic deficit caused by TDP-43 loss. Together, our findings provide evidence that cryptic splicing in these synaptic and membrane excitability genes is not only a downstream marker but instead a direct driver of neuronal dysfunction, establishing a mechanistic link between TDP-43 pathology and neurodegeneration in ALS and FTD.
Early results of COMPPARE, a prospective comparison of outcomes with proton and photon radiation in prostate cancer.
Mendenhall, Nancy P., Bryant, C. A., Katz, Aaron, Morris, Christopher G. , Crisp, Amy M., Odedina, Folakemi, Michalski, Jeff M., Slater, J.D., Choi, Seungtaek, Gayar, H., Sinesi, Christopher, Zlotecki, Robert A., Marshall, David T. , Waddle, Mark R. , Hoppe, Bradford, SHOWALTER, TIMOTHY, DiBiase, Steven J., Lee, W Robert, Chen, Ronald C., Lee, W. Robert , Mendenhall, Nancy P. , Bryant, Curtis, Katz, Aaron J., Crisp, Amy M , DeWees, T.A. , Michalski, Jeff M. , Choi, Seungtaek, Sinesi, Christopher, Showalter, Timothy N. , DiBiase, Steven J. , Chen, Ronald C.

Mayo Clinic

Journal of Clinical Oncology | June 3, 2026 | Volume: 44 | Issue: 17_suppl | Pages: No page available

10.1200/jco.2026.44.17_suppl.lba5012 Get It

LBA5012 Background: There is a critical evidence gap on the relative benefits and harms of proton therapy (PT) compared with photon-based intensity-modulated radiation therapy (IMRT) in prostate cancer. Herein we report early results from COMPPARE, a non-randomized comparative study of outcomes with PT and IMRT in prostate cancer. Methods: Between 2018-2022, 2524 patients from 51 facilities (28 PT and 23 IMRT) enrolled in COMPPARE, including 1501 treated with PT and 1023 treated with IMRT, and were followed prospectively. Treatment naïve patients with localized prostate cancer except those with very high-risk disease were eligible. Treatment was pragmatic with daily standard fractionation (1.8-2.1 Gy) and moderate hypofractionation (2.4-3.1 Gy) permitted. Use of rectal spacers and androgen deprivation were at physician discretion. Patient-reported quality of life data and treatment team-reported toxicity and disease control outcomes were collected at baseline and pre-specified time intervals via VisionTreeOptimalCare; treatment planning and delivery data were collected via the Advanced Treatment Consortium. We analyzed 1404 PT patients and 939 IMRT patients. We report the early primary endpoint of the study, a comparison of patient reported bowel urgency and bowel frequency at 2-years using the EPIC tool, and the secondary endpoints of 2-year CTCAE v5 ≥ grade 2 gastrointestinal toxicity outcomes and 3-year freedom from biochemical progression (FFBP) results reported by the study teams. Results: Study sample size was targeted at 1,500 PT patients and 1,000 IMRT patients, and median follow-up time was 4.0 years. The primary endpoint and secondary toxicity 2-year endpoints focused on the alternative hypothesis of PT superiority. All results include inverse probability of treatment weighting. Using generalized linear mixed effects models, we found there to be no significant difference in EPIC bowel urgency scores (p = 0.324) or bowel frequency scores (p = 0.514) between PT and IMRT cohorts over time up to the 2-year endpoint. For grade 2 gastrointestinal toxicity, the 2-year cumulative incidence was 5.2% for PT and 5.6% for IMRT. Gray’s Test for competing risks showed a hazard ratio (HR) of 0.91 [95% confidence interval (CI): 0.65-1.28, p = 0.6] for PT versus IMRT. The exploratory non-inferiority endpoint of 3-year FFBP was 98.0% for PT and 97.9% for IMRT, and Gray’s Test showed a HR of 0.95 (95% CI: 0.52-1.71, p = 0.90). Conclusions: Analysis of early results of COMPPARE show no significant differences between PT and IMRT in patient reported bowel frequency and urgency, grade ≥2 gastrointestinal toxicity, or FFBP. Assessment of long-term disease control, late toxicity and secondary malignancy will require longer follow-up. Clinical trial information: NCT03561220 .
Multimodal analysis of cell-free DNA identifies epigenetic biomarkers for amyotrophic lateral sclerosis diagnosis and progression
Michels, Sebastian, Chen, Chaorong, Ruf, Wolfgang P., Garcia, M. Madhy Garcia, Arnold, Frederick J. , Wu, Zhuoxing, Bennett, Craig L. , Shams, Daniel, Thompson, Leslie M., Dickson, Dennis W., Petrucelli, Leonard, Dorst, Johannes, Li, Wei, Spada, Albert R. La, Walker, Alyssa C. , Bennett, Craig L , Michels, Sebastian , Ruf, Wolfgang Philipp , Thompson, Leslie Michels , Dickson, Dennis W. , Petrucelli, Leonard , Dorst, Johannes , Prudencio, Mercedes , Spada, Albert R. La

Mayo Clinic

Journal of Clinical Investigation | June 1, 2026 | Volume: 136 | Issue: 11 | Pages: No page available

10.1172/jci191508 | PMID 42222887 Get It

The role of the epigenome in age-related neurodegenerative disorders remains understudied. Here, we analyzed circulating cell-free DNA (cfDNA) from blood to detect methylation changes as a liquid biopsy for Amyotrophic Lateral Sclerosis (ALS). Our study included 20 patients with sporadic ALS, 10 patients with C9orf72-associated ALS, 10 asymptomatic carriers of the C9orf72 repeat expansion mutation, and 21 nondisease control individuals. Following targeted enzymatic methyl-sequencing (EM-seq) of approximately 4 million CpG sites, we detected numerous differentially methylated genes, including several implicated in ALS disease risk and pathogenesis. By integrating multiple epigenetic features, we delineated a distinct epigenetic signature, which achieved an average area under the curve (AUC) of 0.91 ± 0.10 upon receiver operator characteristic (ROC) analysis, which enabled detection of approximately 70% of patients with ALS with close to 100% specificity. Furthermore, we also identified a set of genes whose methylation status significantly correlated with clinical disease progression and cerebrospinal fluid (CSF) neurofilament levels. Our results reveal the potential of cfDNA-based biomarkers to accurately diagnose ALS and potentially predict disease progression.
The Association of Osteoarthritis With De Novo Inflammatory Arthritis in Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Study
Chen, S, Zhang, Zhiqiang, Zhu, Xingxing, Thanarajasingam, Uma , Crowson, Cynthia S. , Zeng, Hu , Chen, Shiju, Zeng, Hu

Mayo Clinic

Arthritis Care & Research | June 1, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/acr.80096 | PMID 42223227 Get It

Objective We aim to identify risk factors to enable stratification of patients' susceptibility to inflammatory arthritis immune‐related adverse events (IA‐irAEs). This retrospective study mainly examines whether preexisting osteoarthritis (OA) increases the likelihood of de novo IA‐irAEs. Methods The prevalence of OA among immune checkpoint inhibitor (ICI)–treated patients who developed IA‐irAE, those who developed other types of irAEs but not IA (non‐IA irAEs), and those who did not develop any irAEs (non‐irAEs) were compared. Electronic medical records were reviewed to extract demographic, clinical, and laboratory data. Group comparisons and logistic regression analyses were performed. Results A total of 181 de novo IA‐irAE patients, 140 non‐IA irAE patients, and 170 non‐irAE patients were included. The prevalence of OA was significantly higher in the IA‐irAE group (69%) than in the non‐IA irAE group (48%) and the non‐irAE group (48%) (both P < 0.001). The IA‐irAE group demonstrated a higher frequency of multisite OA, with more predominant hand involvement (62%) than the non‐IA irAE with OA group (13%) and the non‐irAE with OA group (13%) (both P < 0.001). A family history of autoimmune disease (AID) (odds ratio [OR] 2.03, 95% confidence interval [CI] 1.02–4.05), preexisting OA (OR 2.88, 95% CI 1.85–4.52), and melanoma (OR 2.63, 95% CI 1.56–4.47) were identified as risk factors for the development of IA‐irAE. Conclusion OA was more prevalent among ICI‐treated patients developing IA‐irAE than those who were not. Hand OA was the most common OA pattern in IA‐irAE patients. Preexisting OA, melanoma, and a family history of AID were associated with IA‐irAE.